Abstract
Shigella dysenteriae type 1 and Escherichia coli O157:H7 produce Shiga toxin (Stx) and Shiga toxin (Stx1), respectively and these two toxins are almost identical. E. coli O157:H7 is the major cause of diarrhea-associated hemolytic uremic syndrome. Stx and Stx1 are AB5 type of toxin with a molecular weight of 70 kDa, comprising an enzymaticalyactive A subunit (32 kDa) and five receptor-binding B subunits (7.7 kDa). In this study DNA fragment (289 bp, Gene Bank Accn No. EF685161) coding for B chain of Stx was amplified from S. dysenteriae type1 and cloned. Shiga toxin-binding subunit was expressed and purified in native conditions by affinity and gel permeation chromatography with the yield of 5.1 mg/L in shake flask culture. For the purpose of immunization, the polypeptide was polymerized with glutaraldehyde. Hyper immune serum produced in mice reacted with the purified polypeptide and intact Shiga toxin. The anti- StxB antiserum effectively neutralized the cytotoxicity of Shiga toxin towards HeLa cells.
Keywords: S. dysenteriae type1, Shiga toxin, Shiga like toxin, cytotoxicity, hemolytic uremic syndrome (HUS)
Protein & Peptide Letters
Title: Antibodies Against Recombinant Shiga Toxin Subunit B Neutralize Shiga Toxin Toxicity in HeLa Cells
Volume: 17 Issue: 6
Author(s): Pallavi Gupta, Manglesh Kumar Singh, Padma Singh, Mugdha Tiwari and Ram Kumar Dhaked
Affiliation:
Keywords: S. dysenteriae type1, Shiga toxin, Shiga like toxin, cytotoxicity, hemolytic uremic syndrome (HUS)
Abstract: Shigella dysenteriae type 1 and Escherichia coli O157:H7 produce Shiga toxin (Stx) and Shiga toxin (Stx1), respectively and these two toxins are almost identical. E. coli O157:H7 is the major cause of diarrhea-associated hemolytic uremic syndrome. Stx and Stx1 are AB5 type of toxin with a molecular weight of 70 kDa, comprising an enzymaticalyactive A subunit (32 kDa) and five receptor-binding B subunits (7.7 kDa). In this study DNA fragment (289 bp, Gene Bank Accn No. EF685161) coding for B chain of Stx was amplified from S. dysenteriae type1 and cloned. Shiga toxin-binding subunit was expressed and purified in native conditions by affinity and gel permeation chromatography with the yield of 5.1 mg/L in shake flask culture. For the purpose of immunization, the polypeptide was polymerized with glutaraldehyde. Hyper immune serum produced in mice reacted with the purified polypeptide and intact Shiga toxin. The anti- StxB antiserum effectively neutralized the cytotoxicity of Shiga toxin towards HeLa cells.
Export Options
About this article
Cite this article as:
Gupta Pallavi, Kumar Singh Manglesh, Singh Padma, Tiwari Mugdha and Kumar Dhaked Ram, Antibodies Against Recombinant Shiga Toxin Subunit B Neutralize Shiga Toxin Toxicity in HeLa Cells, Protein & Peptide Letters 2010; 17 (6) . https://dx.doi.org/10.2174/092986610791190291
DOI https://dx.doi.org/10.2174/092986610791190291 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aldose Reductase: A Novel Target for Cardioprotective Interventions
Current Drug Targets Specific Recognition of DNA by Small Molecules
Current Medicinal Chemistry Glycosphingolipid Structure and Function in Membranes
Current Organic Chemistry Genetics in Anti-Platelet Treatment
Current Pharmaceutical Design New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry Novel Therapies for Asthma - Advances and Problems
Current Pharmaceutical Design Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews The Human Pseudoautosomal Region (PAR): Origin, Function and Future
Current Genomics Central Nervous System Circuitry and Peripheral Neural Sympathetic Activity Responsible for Essential Hypertension
Current Neurovascular Research Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Can HIV be Cured? Mechanisms of HIV Persistence and Strategies to Combat It
Current HIV Research Ascaris lumbricoides: An Overview of Therapeutic Targets
Infectious Disorders - Drug Targets Resuscitation of the Newborn in the Delivery Room
Current Pediatric Reviews Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives
Mini-Reviews in Medicinal Chemistry Progress Towards Recombinant Anti-Infective Antibodies
Recent Patents on Anti-Infective Drug Discovery New Treatment Approaches in Acute Myeloid Leukemia: Review of Recent Clinical Studies
Reviews on Recent Clinical Trials Past and Recent Progress of Molecular Imaging Probes for β-Amyloid Plaques in the Brain
Current Medicinal Chemistry Nebulizer Therapy in Pulmonology: Review of the Literature
Current Respiratory Medicine Reviews The Potential for Genetically Altered Microglia to Influence Glioma Treatment
CNS & Neurological Disorders - Drug Targets